<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01863706</url>
  </required_header>
  <id_info>
    <org_study_id>Misoprostol for PPH</org_study_id>
    <nct_id>NCT01863706</nct_id>
  </id_info>
  <brief_title>Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage</brief_title>
  <official_title>Safety and Efficacy of Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hormozgan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hormozgan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post partum Hemorrhage (PPH) is one of three main causes of death in pregnant women. Oxytocin
      is widely used for prevention of PPH. Some studies suggested misoprostol as an alternative
      treatment when Oxytocin isn't available. The aim of this study is to compare the safety and
      efficacy of Oxytocin and misoprostol for prevention of PPH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a double blind randomized controlled trial 400 pregnant women who has vaginal delivery at
      Shariati hospital are assigned into two groups either to receive 20 unite oxytocin in 1000cc
      ringer and 2 placebo tablet or 400mcg oral misoprostol and 2cc normal saline in 1000cc
      ringer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of bleeding</measure>
    <time_frame>1 hour</time_frame>
    <description>within 1 hours after delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin decrease</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrite decrease</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Side effects</measure>
    <time_frame>24 hours</time_frame>
    <description>Diarrhea, Vommiting, Fever, Chills</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Post Partum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400µg oral misoprostol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 IU oxytocin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>400µg oral misoprostol</description>
    <arm_group_label>Misoprostol</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>20 IU Oxytocin</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  were women with singleton pregnancy

          -  with cephalic presentation

          -  who had NVD spontaneously or by induction

        Exclusion Criteria:

          -  placenta previa

          -  placental detachment

          -  coagulation problems

          -  previous CS

          -  macrosomia

          -  Polyhydramnios

          -  and uncontrolled asthma
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minoo Rajaei, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hormozgan University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zohreh Shahboodaghi, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Hormozgan University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hormozgan University of Medical Sciences</name>
      <address>
        <city>Bandar Abbas</city>
        <state>Hormozgan</state>
        <zip>097145-3388</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2013</study_first_submitted>
  <study_first_submitted_qc>May 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hormozgan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Hamidreza Mahboobi</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Misoprostol</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Post Partum Hemorrhage (PPH)</keyword>
  <keyword>Third stage of labour</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

